Adherence Reimagined: Lessons from a Global Phase 2 Ophthalmology Study

Insights into Real-Time Oversight, Behavior Change, and Operational Efficiency

By Med-Con

Executive Summary

Clinical trial success depends on more than just protocol design—it relies on how reliably medications are taken as prescribed. In a recent global Phase 2 Ophthalmology study, a complex titration model paired with daily dosing posed a significant challenge for both patient adherence and sponsor oversight. Med-Con served as the sole digital adherence tool for sites and countries that chose to participate, while paper-based drug accountability remained the fallback for others.

The results were clear: with Med-Con, adherence rates exceeded 90%. In contrast, sites using traditional manual methods typically fell between 64% and 78%. The difference wasn't just in data quality—it was in operational confidence, regulatory readiness, and the ability to make timely decisions.

This white paper explores the key lessons from this study: why real-time oversight matters, how optional implementation leads to avoidable inconsistencies, and what sponsors can do to embed adherence solutions without disrupting timelines or supply chains. The takeaway is simple—when you build adherence into your process early, you don’t just improve compliance—you gain control.

1. The Adherence Challenge in Complex Trials

In global trials with complex dosing regimens, ensuring that patients follow instructions correctly is a foundational requirement—but one that is often underestimated. In this Ophthalmology study, patients followed a titration model dependent on lab data, making accurate adherence not only critical for efficacy but also for safety.

Historically, adherence has been tracked through patient-reported diaries or site-entered pill counts. These approaches are subject to error, delay, and variability across regions. Inconsistent tracking can lead to protocol deviations, dosing errors, and costly rework—not to mention regulatory risk.

2. A Real-Time Oversight Engine for Adherence

Med-Con was deployed across a broad selection of participating sites as the primary adherence tracking solution. The tool enabled real-time capture of dosing behavior, supported by a digital interface designed for ease of use by both patients and study staff. When lab values indicated a need to adjust dosage, the oversight engine ensured titration adjustments were made on time and logged accurately.

Sponsors and study teams had access to live dashboards that surfaced patterns across patients, sites, and countries—offering unprecedented visibility into behavior trends, non-compliance risks, and adherence patterns.

Key operational advantages included:

• Early identification of adherence gaps before protocol deviations occurred
• Reduced manual reconciliation work for clinical monitors
• Stronger data integrity and audit readiness

3. Data-Driven Impact

The difference between paper and digital adherence tracking was stark. In sites using Med-Con:

• Adherence consistently exceeded 90%, even with daily dosing and titration
• Sponsor teams had real-time oversight, reducing the lag time in critical decisions
• Sites experienced a lighter administrative burden, reporting faster workflows

By contrast, paper-based sites reported adherence between 64% and 78%, with greater effort needed to verify logs, clarify inconsistencies, and track down missed doses.

4. The Cost of Making Adherence Optional

One of the clearest takeaways from this trial was the behavioral effect of implementation choices. Where the Med-Con tool was made optional, site adoption varied—and not always based on need. Many sites defaulted to their familiar paper processes simply because they were familiar with the paper process.

This exposed a critical truth: when tools are optional, behavior defaults to what’s routine—even when that routine is inefficient.

To get the full value from digital adherence tools:

• Adoption should be planned early in the study timeline
• Training and site workflows should embed the technology
• Optional use should be discouraged or tightly managed

5. Lessons for the Industry

This study illuminated several important opportunities for the broader clinical research community:

• Adherence is a systems issue, not just a patient behavior problem.
  Real-time tracking enables sponsors to prevent issues, not just document them.
• Digital solutions must be normalized—not “extra.”
  Optional tools introduce inconsistency and reduce overall impact.
• Early planning prevents delays.
  When integrated early, adherence platforms like Med-Con do not disrupt production lines or trial startup timelines.
• Sustainability and cost savings are real.
  Reduced paper and electronic waste compared to other medication adherence tools, streamlined data collection, and fewer protocol deviations translate into meaningful operational efficiencies.

Conclusion

Adherence is one of the most controllable variables in clinical trials—if you have the right tools in place. Med-Con’s experience in this global Ophthalmology study proves that real-time oversight doesn’t just improve adherence; it builds a foundation for smarter trial execution, better patient outcomes, and fewer surprises.

Sponsors that plan early, require adoption, and align their teams around a digital-first mindset are positioned to get more out of every dose, every data point, and every day of their study.

Call to Action

See how Med-Con can support your next trial.
Schedule a demo to explore our real-time adherence platform and oversight dashboard in action. Visit us at www.medcontech.com

This white paper reflects aggregate insights drawn from Med-Con’s past project work and industry experience. Specific trial or sponsor details have been anonymized to respect confidentiality.